SERES THERAPEUTICS
Seres Therapeutics is a clinical-stage biotherapeutic company that develops ecobiotic therapeutic products. They engaged in developing biological drugs which are referred to as ecobiotic microbiome therapeutics.
SERES THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.serestherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+1 617 945 9626
Total Funding:
402.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Nginx Sitelinks Search Box
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
NextCure
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Advisor
2019-12-01
Board_member
Current Employees Featured
Carlo Tanzi Vice President, Head of Investor Relations and Corporate Communications @ Seres Therapeutics
Vice President, Head of Investor Relations and Corporate Communications
2018-01-01
David Berry Founder @ Seres Therapeutics
Founder
2010-01-01
Eric Shaff CFO @ Seres Therapeutics
CFO
David Cooke CSO and Executive Vice President of R&D @ Seres Therapeutics
CSO and Executive Vice President of R&D
Matthew Henn Executive VP, Chief Scientific Officer @ Seres Therapeutics
Executive VP, Chief Scientific Officer
2019-02-01
Stephen Berenson Chairman Of The Board @ Seres Therapeutics
Chairman Of The Board
2019-08-01
Jennifer Russo Wortman Vice President, R&D - Clinical Discovery & Research Technologies @ Seres Therapeutics
Vice President, R&D - Clinical Discovery & Research Technologies
2019-01-01
David A. Arkowitz CFO and Head of Business Development @ Seres Therapeutics
CFO and Head of Business Development
2021-06-01
Paula A. Cloghessy EVP, Chief People Officer @ Seres Therapeutics
EVP, Chief People Officer
2022-02-07
David Berry Co-Founder @ Seres Therapeutics
Co-Founder
Founder
Stock Details
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Seres Therapeutics
CARB-X
CARB-X investment in Grant - Seres Therapeutics
Nestlé Health Science
Nestlé Health Science investment in Series D - Seres Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series C - Seres Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series B - Seres Therapeutics
Alexandria Venture
Alexandria Venture investment in Series B - Seres Therapeutics
Enso Ventures
Enso Ventures investment in Series B - Seres Therapeutics
Mayo Clinic
Mayo Clinic investment in Series B - Seres Therapeutics
Enso Ventures
Enso Ventures investment in Series A - Seres Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series A - Seres Therapeutics
Newest Events participated
Participated in South Summit 2017
on 2017-10-04 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-08 | Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer |
Official Site Inspections
http://www.serestherapeutics.com Semrush global rank: 1.94 M Semrush visits lastest month: 11.12 K
- Host name: 14.165.188.35.bc.googleusercontent.com
- IP address: 35.188.165.14
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Seres Therapeutics"
About Us - Seres Therapeutics
From 1998 to 2007, she served as president and director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies. Dr. …See details»
Our Platform - Seres Therapeutics
Our in-house manufacturing organization integrates process development, current Good Manufacturing Practices (cGMP), Quality Control, and Quality Assurance. These capabilities …See details»
Seres Therapeutics - LinkedIn
Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as …See details»
Seres Therapeutics - Crunchbase Company Profile
Seres Therapeutics experienced a 12% loss in holdings value for institutional and retail investors. The company reported a third-quarter 2024 earnings loss of US$0.33 per share, an improvement from the US$0.37 loss in the third quarter …See details»
FDA Grants Breakthrough Therapy Designation to Seres …
Dec 9, 2024 For more information, please visit www.serestherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the …See details»
Seres Therapeutics - PitchBook
Seres Therapeutics General Information Description. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in …See details»
Seres Therapeutics - VentureRadar
"Seres Health is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology …See details»
Seres Therapeutics - Company Profile & Staff Directory - ContactOut
Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products, novel drugs to treat important diseases by …See details»
Seres Therapeutics to Participate in 2025 J.P. Morgan …
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. …See details»
Seres Therapeutics
Seres TherapeuticsSee details»
Seres Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap
Mr. Shaff continued, “We are emerging from this transaction a more streamlined organization, with our debt fully retired and an investment plan focused on advancing our promising pipeline …See details»
Our Programs - Seres Therapeutics
CCF is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life of children and adults affected by these …See details»
Seres Therapeutics - Overview, News & Similar companies
Seres Therapeutics contact info: Phone number: (617) 945-9626 Website: www.serestherapeutics.com What does Seres Therapeutics do? Seres Therapeutics, Inc. is a …See details»
Seres Therapeutics, Inc. (MCRB) Company Profile & Overview
Jun 26, 2015 Ticker Symbol: MCRB: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001609809: CUSIP Number: 81750R102: ISIN …See details»
Working At Seres Therapeutics: Company Overview and Culture
Mar 14, 2024 www.serestherapeutics.com. Organization Type. Public. CEO. Geoffrey von Maltzahn. Social Media. Seres Health is a clinical-stage therapeutics company focused on …See details»
Seres Therapeutics Company Profile - Office Locations ... - Craft
Seres Therapeutics has 5 employees at their 1 location and $126.33 m in annual revenue in FY 2023. See insights on Seres Therapeutics including office locations, competitors, revenue, …See details»
Inside Seres - Seres Therapeutics
A highlight of working at Seres is the ability to collaborate with scientists of many different backgrounds, which has given me the opportunity to learn new skill sets and think of problems …See details»
Seres Therapeutics Announces Completion of VOWST™ Asset Sale …
Sep 30, 2024 Seres Therapeutics, Inc. Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple …See details»
Seres Therapeutics Stockholders Approve Sale of VOWST™ to …
CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced …See details»
Seres Therapeutics Reports Third Quarter 2024 Financial Results …
Nov 13, 2024 Following completion of the VOWST sale, Seres is a more streamlined organization with no outstanding debt and a projected lower cash burn rate. Seres’ headcount …See details»